CEO
mimiX Biotherapeutics
MimiX Biotherapeutics utilizes Sound Induced Morphogenesis to biofabricate artificial human organs and tissues by manipulating sound profiles to pattern biological materials in a contactless environment. This technology addresses the challenge of creating complex, functional tissues for regenerative medicine, enhancing the scalability and accessibility of biofabrication methods.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$7.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Creating complex, functional human tissues and organs for regenerative medicine is challenging due to limitations in current biofabrication methods, which often struggle with scalability, precision, and maintaining cell viability. Traditional bioprinting techniques may not fully replicate the intricate three-dimensional structures and cellular organization found in native tissues.
Solution
MimiX Biotherapeutics offers a biofabrication platform based on Sound Induced Morphogenesis (SIM) technology, which uses acoustic waves to precisely pattern biological materials in a contactless environment. This method enables the creation of three-dimensional tissue constructs by remotely controlling the condensation and organization of cells, organoids, and micrografts. The SIM process replicates natural tissue development by controlling bioactive condensation and pattern formation, resulting in engineered tissues with microvascular networks. The technology aims to improve the scalability and precision of tissue engineering, while maintaining cell viability and metabolic activity.
Target Audience
The primary target audience includes researchers and clinicians in regenerative medicine, drug development, and tissue engineering, as well as strategic partners in industry and academia.
Features
- CymatiX™: A SIM-based tool for creating physiologically relevant engineered tissue constructs and in vitro models.
- Contactless acoustic wave technology for gentle manipulation of biological materials.
- Ability to pattern living building blocks, including cells, spheroids, organoids, and micrografts.
- Capability to pattern particles such as calcium phosphate, hydrogel precursors, and polymer microbeads.
- Control over cell density enhancement and pattern formation at scales from micrometers to centimeters.
- FastSkin®: An autologous tissue product for complex wound care, combining micrografting with SIM technology.
- Biomaterials kits with natural and synthetic materials for various crosslinking strategies.